TG Therapeutics, Inc.
TGTX
$37.25
-$0.10-0.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 501.31% | -43.60% | 164.25% | 25.73% | -112.65% |
| Total Depreciation and Amortization | -18.18% | -42.11% | -34.48% | -23.68% | -47.95% |
| Total Amortization of Deferred Charges | -23.77% | -32.51% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -25.29% | 77.24% | 9.75% | -7.99% | -6.48% |
| Change in Net Operating Assets | -90.86% | -198.41% | -75.79% | 24.64% | 79.93% |
| Cash from Operations | -110.09% | -320.47% | 167.45% | 37.87% | -115.78% |
| Capital Expenditure | 12.50% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 269.81% | -627.48% | 119.07% | 79.32% | -48.05% |
| Cash from Investing | 269.15% | -628.84% | 119.07% | 79.32% | -48.05% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 186.43% | 47.41% | 1,250.00% | -- | -- |
| Repurchase of Common Stock | -207.63% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.39% | -- | -- | -- | -- |
| Cash from Financing | -104.52% | 99,495.56% | 1,250.00% | 1,100.00% | -100.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -114.10% | 1,418.49% | 142.61% | 69.89% | -207.55% |
